FOLH1 and posterior cortical atrophy: First-in-human administration of [99mTc]Tc-PSMA-I&S in a patient with metastatic castration-resistant PCa and one with histologically confirmed primary PCa showed high plasma protein binding of the tracer (94%), which promoted its efficient uptake in PCa lesions over time, with a steady increase in lesion-to-background ratios up to 21 h after injection [115].